LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Programmed cell death protein 1 (PD-1) blockade therapy shows variable efficacy in cancer treatment, with response rates ranging from 4% to 70%.
• Immune checkpoints, such as PD-1 and Lymphocyte Activation Gene-3 (LAG-3), play crucial roles in regulating immune responses and can be exploited by tumors to evade immune surveillance.
• There is a critical need for novel immunotherapy strategies to enhance anti-tumor responses in a broader patient population.

Purpose of the Study:

• To explore Lymphocyte Activation Gene-3 (LAG-3) as a potential therapeutic target in cancer immunotherapy.
• To evaluate the efficacy of combining LAG-3 blockade with PD-1 blockade therapy.

Main Methods:

• Review of preclinical and clinical studies investigating LAG-3 function and blockade.
• Analysis of the combined effects of LAG-3 and PD-1 inhibition in cancer models and patient cohorts.

Main Results:

• LAG-3 is an immune checkpoint receptor expressed on activated immune cells that contributes to tumor immune escape.
• LAG-3 blockade has demonstrated the ability to overcome resistance to PD-1 inhibitors in preclinical and clinical settings.
• Combination therapy involving both LAG-3 and PD-1 blockade has shown significant clinical efficacy across various cancer types.

Conclusions:

• Synchronous inhibition of LAG-3 and PD-1 represents a promising novel strategy for improving cancer immunotherapy outcomes.
• Targeting both LAG-3 and PD-1 pathways may enhance anti-tumor immunity and increase response rates in patients who do not benefit from PD-1 monotherapy.